- Home
- L vs DGX Comparison
L vs DGX Comparison
Compare L & DGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- L
- DGX
- Stock Information
- Founded
- L 1969
- DGX 1967
- Country
- L United States
- DGX United States
- Employees
- L N/A
- DGX N/A
- Industry
- L Property-Casualty Insurers
- DGX Medical Specialities
- Sector
- L Finance
- DGX Health Care
- Exchange
- L Nasdaq
- DGX Nasdaq
- Market Cap
- L 18.1B
- DGX 19.2B
- IPO Year
- L N/A
- DGX 1996
- Fundamental
- Price
- L $87.96
- DGX $176.59
- Analyst Decision
- L
- DGX Buy
- Analyst Count
- L 0
- DGX 14
- Target Price
- L N/A
- DGX $185.07
- AVG Volume (30 Days)
- L 669.9K
- DGX 1.4M
- Earning Date
- L 05-05-2025
- DGX 04-22-2025
- Dividend Yield
- L 0.28%
- DGX 1.82%
- EPS Growth
- L N/A
- DGX 6.41
- EPS
- L 6.09
- DGX 7.91
- Revenue
- L $17,773,000,000.00
- DGX $10,158,000,000.00
- Revenue This Year
- L N/A
- DGX $10.28
- Revenue Next Year
- L N/A
- DGX $4.05
- P/E Ratio
- L $14.43
- DGX $22.24
- Revenue Growth
- L 8.71
- DGX 9.38
- 52 Week Low
- L $73.15
- DGX $135.47
- 52 Week High
- L $92.42
- DGX $179.32
- Technical
- Relative Strength Index (RSI)
- L 55.07
- DGX 57.67
- Support Level
- L $85.10
- DGX $175.25
- Resistance Level
- L $89.39
- DGX $178.74
- Average True Range (ATR)
- L 1.52
- DGX 3.57
- MACD
- L 0.26
- DGX 0.13
- Stochastic Oscillator
- L 71.73
- DGX 69.39
About L Loews Corporation
Loews Corp is a holding company along with its subsidiary engaged in commercial property and casualty insurance, transportation and storage of natural gas and natural gas liquids, operation of a chain of hotels, and also in the manufacture of rigid plastic packaging solutions. It has four reportable segments comprised of three individual consolidated operating subsidiaries, CNA Financial Corporation, Boardwalk Pipeline Partners, LP and Loews Hotels Holding Corporation; and the Corporate segment.
About DGX Quest Diagnostics Incorporated
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.